ArticleMolecular plant2016
Compartmentalized Metabolic Engineering for Artemisinin Biosynthesis and Effective Malaria Treatment by Oral Delivery of Plant Cells.
Article in Molecular plant, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 108 citations in OpenAlex.
- Exploring specialized metabolic pathways in medicinal plants with single-cell and spatial omics.Acta pharmaceutica Sinica. B · 2026Review
- Editing and synthetic engineering of chloroplast genomes.Plant communications · 2026Review
- NPlant biotechnology journal · 2025Article
- Unlocking the potential of3 Biotech · 2025Review
- Dihydroartemisinic acid dehydrogenase-mediated alternative route for artemisinin biosynthesis.Nature communications · 2025Article
- Navigating the challenges of engineering composite specialized metabolite pathways in plants.The Plant journal : for cell and molecular biology · 2025Review
- Engineering Plant Cell Fates and Functions for Agriculture and Industry.ACS synthetic biology · 2024Review
- Heterologous expression of taxane genes confers resistance to fall armyworm in Nicotiana benthamiana.Plant cell reports · 2024Article
- Characterization of intracellular membrane structures derived from a massive expansion of endoplasmic reticulum (ER) membrane due to synthetic ER-membrane-resident polyproteins.Journal of experimental botany · 2024Article
- Plant Engineering to Enable Platforms for Sustainable Bioproduction of Terpenoids.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Heterologous Production of Artemisinin inBio-protocol · 2023Article
- Localization of Sesquiterpene Lactones Biosynthesis in Flowers ofMolecules (Basel, Switzerland) · 2023Article
- Current Status and De Novo Synthesis of Anti-Tumor Alkaloids inMetabolites · 2023Review
- Plants as Sources of Natural and Recombinant Antimalaria Agents.Molecular biotechnology · 2022Review
- From Plant to Yeast-Advances in Biosynthesis of Artemisinin.Molecules (Basel, Switzerland) · 2022Review
- Reconstitution of monoterpene indole alkaloid biosynthesis in genome engineered Nicotiana benthamiana.Communications biology · 2022Article
- Review
- Pathway Engineering, Re-targeting, and Synthetic Scaffolding Improve the Production of Squalene in Plants.ACS synthetic biology · 2022Article
- CRISPR-Cas gene editing technology and its application prospect in medicinal plants.Chinese medicine · 2022Review
- Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Artemisinin is highly effective against drug-resistant malarial parasites, which affects nearly half of the global population and kills >500 000 people each year. The primary cost of artemisinin is the very expensive process used to extract and purify the drug from Artemisia annua. Elimination of this apparently unnecessary step will make this potent antimalarial drug affordable to the global population living in endemic regions. Here we reported the oral delivery of a non-protein drug artemisinin biosynthesized (∼0.8 mg/g dry weight) at clinically meaningful levels in tobacco by engineering two metabolic pathways targeted to three different cellular compartments (chloroplast, nucleus, and mitochondria). The doubly transgenic lines showed a three-fold enhancement of isopentenyl pyrophosphate, and targeting AACPR, DBR2, and CYP71AV1 to chloroplasts resulted in higher expression and an efficient photo-oxidation of dihydroartemisinic acid to artemisinin. Partially purified extracts from the leaves of transgenic tobacco plants inhibited in vitro growth progression of Plasmodium falciparum-infected red blood cells. Oral feeding of whole intact plant cells bioencapsulating the artemisinin reduced the parasitemia levels in challenged mice in comparison with commercial drug. Such novel synergistic approaches should facilitate low-cost production and delivery of artemisinin and other drugs through metabolic engineering of edible plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.